Cantor Fitzgerald Predicts Arvinas FY2025 Earnings

Arvinas, Inc. (NASDAQ:ARVN) – Cantor Fitzgerald issued their FY2025 EPS estimates for Arvinas in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings of ($6.11) per share for the year. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.20. The business had revenue of $102.40 million for the quarter, compared to analyst estimates of $60.56 million. During the same quarter last year, the company earned ($1.18) EPS. Arvinas’s revenue was up 196.0% compared to the same quarter last year.

Other equities research analysts have also issued reports about the company. Stephens initiated coverage on Arvinas in a research report on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price on the stock. Oppenheimer cut their price objective on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Guggenheim restated a “buy” rating on shares of Arvinas in a research report on Thursday, December 12th. BTIG Research initiated coverage on Arvinas in a report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price target on the stock. Finally, BMO Capital Markets decreased their price objective on Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Arvinas presently has an average rating of “Moderate Buy” and a consensus price target of $63.50.

Arvinas Trading Down 1.9 %

Shares of Arvinas stock opened at $18.22 on Wednesday. Arvinas has a twelve month low of $17.08 and a twelve month high of $53.08. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -3.90 and a beta of 1.87. The business’s 50 day simple moving average is $21.12 and its 200-day simple moving average is $24.46.

Institutional Trading of Arvinas

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV boosted its holdings in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after buying an additional 1,255 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Arvinas by 228.8% during the 4th quarter. SG Americas Securities LLC now owns 32,424 shares of the company’s stock worth $622,000 after acquiring an additional 22,564 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Arvinas by 0.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock worth $2,694,000 after acquiring an additional 777 shares during the last quarter. Nordea Investment Management AB raised its position in shares of Arvinas by 4.1% during the fourth quarter. Nordea Investment Management AB now owns 232,886 shares of the company’s stock worth $4,404,000 after purchasing an additional 9,196 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock valued at $57,371,000 after purchasing an additional 367,343 shares during the last quarter. 95.19% of the stock is currently owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.